Category: Medical Breakthroughs

You no longer need to grow a Marijuana plant to extract THC and CBD. You can get both by using Brewer’s Yeast and Sugar. You also get purer products. For example you can make CBD without the worry of it also containing THC.

This is revolutionary. It could eliminate huge Marijuana plant grow operations. It could also produce Cannabinoids which cannot be obtained from Marijuana plants. The consistency and purity of the produced product can be regulated to be uniform from batch to batch. This new process offers great potential in finding, via Medical Research Studies, new medical benefits of THC, CBD and other Cannabinoids.

Cristina Sánchez has been studying Cannabis for fifteen years at Complutense University in Madrid Spain. She has discovered that THC from Cannabis can kill Cancer cells.

Being able to produce Medical Cannabis products like THC in a pure form using Brewer’s Yeast opens up a lot of potential in the Medical field as you can maintain purity and quality in each batch produced. For example, there have been documented cases of patients who have seizures and are helped by CBD. You also eliminate the potential use of Pesticides in Plant Grow Operations.

Studies in mice and rats have shown that cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow. Laboratory and animal studies have shown that cannabinoids may be able to kill cancer cells while protecting normal cells.

A study in mice showed that cannabinoids may protect against inflammation of the colon and may have potential in reducing the risk of colon cancer, and possibly in its treatment.

A laboratory study of cannabidiol (CBD) in estrogen receptor positive and estrogen receptor negative breast cancer cells showed that it caused cancer cell death while having little effect on normal breast cells. Studies in mouse models of metastatic breast cancer showed that cannabinoids may lessen the growth, number, and spread of tumors.

A review of 34 studies of cannabinoids in glioma tumor models found that all but one study showed that cannabinoids can kill cancer cells without harming normal cells.A laboratory study of cannabidiol (CBD) in human glioma cells showed that when given along with chemotherapy, CBD may make chemotherapy more effective and increase cancer cell death without harming normal cells. Studies in mouse models of cancer showed that CBD together with delta-9-THC may make chemotherapy such as temozolomide more effective.

The use of Cannabis for medicinal purposes dates back to ancient times (see Question 3).

By federal law, the possession of Cannabis is illegal in the United States outside of approved research settings. However, a growing number of states, territories, and the District of Columbia have enacted laws to legalize medical marijuana (see Question 1).

The main active cannabinoid in Cannabis is delta-9-THC. Another active cannabinoid is cannabidiol (CBD), which may relieve pain, lower inflammation, and decrease anxiety without causing the “high” of delta-9-THC (see Question 2).

Cannabinoids can be taken by mouth, inhaled, or sprayed under the tongue (see Question 5).

Cannabis and cannabinoids may have benefits in treating the symptoms of cancer or the side effects of cancer therapies. There is growing interest in treating children for symptoms such as nausea with Cannabis and cannabinoids, although studies are limited (see Question 7).

Note from Vince:This is am extremely important change as the Cannabis grown by NIDA is an uncommon variety and apparently low in THC. The FDA could approve a Medical Study of the use of high THC Cannabis in the treatment of Cancer, but NIDA always had the final word. If they approved a medical study (their usual common response was “No”) the study had to use the NIDA supplied Cannabis variety.

WASHINGTON, D.C. — Today, the Drug Enforcement Administration (DEA) announced their intention to grant licenses to additional marijuana growers for research, thereby ending the DEA-imposed 48-year monopoly on federally legal marijuana. Since 1968, the University of Mississippi, under contract to the National Institute on Drug Abuse (NIDA), has maintained the only facility in the United States with federal permission to grow marijuana for research.

“It’s a complete and total end of the NIDA monopoly! There has been no production monopoly on any other Schedule I substance, like MDMA or LSD—only the cannabis plant. Licensing non-government cannabis producers, and thereby creating a path to FDA approval, will finally facilitate the removal of marijuana from Schedule I, and ultimately allow patients to receive insurance coverage for medical marijuana,” said Rick Doblin, Ph.D., Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS).

MAPS has been working to eliminate this cannabis research blockade since 1999. NIDA’s marijuana is eligible for research, but cannot be sold as a prescription medicine, making it unacceptable to the Food and Drug Administration (FDA) for use in future Phase 3 studies. Ending the monopoly finally allows for a pathway to FDA approval for marijuana, which would thereby trigger rescheduling.

In 2001, MAPS partnered with University of Massachusetts-Amherst Professor Lyle Craker, Ph.D., to apply for a DEA license and end the monopoly. In 2007, after years of bureaucratic delays and lengthy legal hearings, a DEA Administrative Law Judge (ALJ) recommended that it would be in the public’s interest to grant Craker the license. In 2009, after almost two more years of delays and less than a week before the inauguration of President Obama, former DEA Administrator Michelle Leonhart rejected the ALJ recommendation. In 2011, Craker sued the DEA in the U.S. First Circuit Court of Appeals. In its 2013 decision, the Court uncritically accepted the DEA’s arguments that NIDA’s monopoly provided “an adequate supply produced under adequately competitive conditions.”

Since the 2013 decision, Craker’s argument that NIDA does not have an adequate supply has become significantly more apparent. NIDA has been unable to provide the strains requested for MAPS’ long-delayed Phase 2 clinical trial of smoked marijuana to treat symptoms of posttraumatic stress disorder (PTSD) in 76 U.S. veterans. As a result, the study is proceeding with lower potency marijuana than what MAPS researchers requested.

The DEA has previously claimed that U.S. international treaty obligations under the United Nations Single Convention on Narcotic Drugs (Single Convention) require a federal monopoly, but in April 2016, the State Department released a statement clarifying that the Single Convention does not in fact limit the number of U.S. marijuana producers.

Furthermore, the DEA’s 2009 rejection of the ALJ recommendation to license Craker relied heavily on a U.S. Department of Health and Human Services (HHS) protocol review process, which was eliminated in 2015.

MAPS’ upcoming Phase 2 clinical trial of marijuana for PTSD in veterans is in collaboration with investigators in Phoenix, Arizona, and at Johns Hopkins University, the University of Colorado, and the University of Pennsylvania. The study is funded by a $2.15 million grant to MAPS from the State of Colorado. The study has received full regulatory approval, and will be the first randomized controlled trial of whole plant marijuana as a treatment for PTSD.

Founded in 1986, MAPS is a non-profit research and educational organization working to evaluate the safety and efficacy of botanical marijuana as a potential prescription medicine for specific medical uses approved by the FDA.

Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.

The Parents “were putting Cannabinoid Oil on the baby’s pacifier twice a day, increasing the dose… And within two months there was a dramatic reduction”.

“Dr. Courtney pointed out that the success of the Cannabis approach means that “this child, because of that, is not going to have the long-term side effects that would come from a very high dose of chemotherapy or radiation“”.

Dr. Dominic D’Agostino is an Assistant Professor at the University of South Florida College Of Medicine, Molecular Pharmacology & Physiology where he develops and tests Metabolic Therapies, including alternative energy substrates and ketogenic agents for neurological disorders, Cancer and wound healing.

While studying the effects of gasses on the brains of Navy Seal divers, he developed an approach for metabolically starving Cancer Cells through diet and compressed oxygen, replacing chemotherapy, surgery, or radiation.

Abstract

Egg activation refers to events required for transition of a gamete into an embryo, including establishment of the polyspermy block, completion of meiosis, entry into mitosis, selective recruitment and degradation of maternal mRNA, and pronuclear development. Here we show that zinc fluxes accompany human egg activation. We monitored calcium and zinc dynamics in individual human eggs using selective fluorophores following activation with calcium-ionomycin, ionomycin, or hPLCζ cRNA microinjection. These egg activation methods, as expected, induced rises in intracellular calcium levels and also triggered the coordinated release of zinc into the extracellular space in a prominent “zinc spark.” The ability of the gamete to mount a zinc spark response was meiotic-stage dependent. Moreover, chelation of intracellular zinc alone was sufficient to induce cell cycle resumption and transition of a meiotic cell into a mitotic one. Together, these results demonstrate critical functions for zinc dynamics and establish the zinc spark as an extracellular marker of early human development.

The article for which you have requested permission has been distributed under a Creative Commons CC-BY license (please see the article itself for the license version number). You may reuse this material without obtaining permission from Nature Publishing Group, providing that the author and the original source of publication are fully acknowledged, as per the terms of the license.
For license terms, please see http://creativecommons.org/

Getting any form of cancer can be life changing. The medical procedures used to eliminate the Cancer can also have life changing side effects.

Removing a Cancerous Prostate is one present way to deal with Colon Cancer.

There is a novel new procedure which has already been approved for use in Mexico. It may soon be approved for use in Europe.

The key part is that the procedure is minimally invasive. If the Cancerous Tumor can be reached by thin optic fibers then this procedure could be an effective way to treat said Tumor.The thin optic fiber is needed to direct the Laser light at the Tumor. “Laser light activation of an intravenous infusion of Tookad Soluble releases short-lived toxic oxygen and nitric oxide radicals that destroy the Cancer tumor’s blood vessels and thereby kill the tumorous cells”.The Tookad Soluble drug is eliminated from the body in less than 6 hours. Without the Laser Light activation the Tookad Soluble has no effect on other cells or organ. Ultra Sound is used to feed and direct the Optic Fibres into the patients body.

This new technology was developed by the Yeda Research and Development Company, of the Weizmann Institute in collaboration with Steba Biotech of Luxembourg. Steba Biotech received the license for Tookad Soluble from Yeda Research and Development Company.

Since this procedure can target Cancer Tumors where a Fibre Optic strand could reach the tumor, then the door may be open to treat many other forms of Cancer. More research and Clinical Studies are underway.

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner. There could be unintentional errors or omissions in this post. Always refer to the official sites to confirm details and any ongoing changes or updates. This post is subject to change without notice.

This post is about research being conducted in Australia, which shows great promise in the treatment of Alzheimers. Apparently some memory loss could be reversed, in mice so far, by using their protocol and Scanning UltraSound.

The following is the Abstract (posted for Educational purposes). A link is provided further down to access the complete text and a downloadable PDF.

Abstract

Amyloid-β (Aβ) peptide has been implicated in the pathogenesis of Alzheimer’s disease (AD). We present a nonpharmacological approach for removing Aβ and restoring memory function in a mouse model of AD in which Aβ is deposited in the brain. We used repeated scanning ultrasound (SUS) treatments of the mouse brain to remove Aβ, without the need for any additional therapeutic agent such as anti-Aβ antibody. Spinning disk confocal microscopy and high-resolution three-dimensional reconstruction revealed extensive internalization of Aβ into the lysosomes of activated microglia in mouse brains subjected to SUS, with no concomitant increase observed in the number of microglia. Plaque burden was reduced in SUS-treated AD mice compared to sham-treated animals, and cleared plaques were observed in 75% of SUS-treated mice. Treated AD mice also displayed improved performance on three memory tasks: the Y-maze, the novel object recognition test, and the active place avoidance task. Our findings suggest that repeated SUS is useful for removing Aβ in the mouse brain without causing overt damage, and should be explored further as a noninvasive method with therapeutic potential in AD.

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner. There could be unintentional errors or omissions in this post. Always refer to the official sites to confirm details and any ongoing changes or updates. This post is subject to change without notice. The Study Abstract has been included in this post for Educational Purposes and so is covered by the Fair Use component of Copyright. Uniquely Toronto makes no claims regarding the copyright or other rights to the published material. Also complete links have been included to the Science Translational Medicine site.

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner. There could be unintentional errors or omissions in this post. Always refer to the official sites to confirm details and any ongoing changes or updates. This post is subject to change without notice. Posting links is covered under the Fair Use Provision of Copyright. Permission was also granted by the Business Standard site to share their post link.

Trimethylamine (TMA) N-oxide (TMAO), a gut-microbiota-dependent metabolite, both enhances atherosclerosis in animal models and is associated with cardiovascular risks in clinical studies. Here, we investigate the impact of targeted inhibition of the first step in TMAO generation, commensal microbial TMA production, on diet-induced atherosclerosis. A structural analog of choline, 3,3-dimethyl-1-butanol (DMB), is shown to non-lethally inhibit TMA formation from cultured microbes, to inhibit distinct microbial TMA lyases, and to both inhibit TMA production from physiologic polymicrobial cultures (e.g., intestinal contents, human feces) and reduce TMAO levels in mice fed a high-choline or L-carnitine diet. DMB inhibited choline diet-enhanced endogenous macrophage foam cell formation and atherosclerotic lesion development in apolipoprotein e−/− mice without alterations in circulating cholesterol levels. The present studies suggest that targeting gut microbial production of TMA specifically and non-lethal microbial inhibitors in general may serve as a potential therapeutic approach for the treatment of cardiometabolic diseases.”

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner. There could be unintentional errors or omissions in this post. Always refer to the official sites to confirm details and any ongoing changes or updates. This post is subject to change without notice. Neither Vincent Banial nor Uniquely Toronto make any claims to the copyright to the material discussed in the above post. Copyright is retained by the authors of the study and with the journal Cell.

This post is not meant to be medical advice. Always seek the help and advice of your on Medial Doctor. This post is strictly for “Educational Purposes”. Our initial post about TMAO (posted on April 08 2013 is one of our most popular posts. Students and researches from all around the globe have visited our site just to read that educational post.

Knowledge is power and I strive to give back to humanity, by posting information for educational purposes, such as this post.

This post is also licensed to share under the Creative Commons License

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner. There could be unintentional errors or omissions in this post. Always refer to the official sites to confirm details and any ongoing changes or updates. This post is subject to change without notice.

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner. There could be unintentional errors or omissions in this post. This post is subject to change without notice.

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner. There could be unintentional errors or omissions in this post. Always refer to the official sites to confirm details and any ongoing changes or updates. This post is subject to change without notice.

Disclaimer: Any Trademarks mentioned in this post are owned by the respective Trademark owner. There could be unintentional errors or omissions in this post. This post is subject to change without notice.

Powerful Men Cheat on their spouses. Powerful Women Cheat on their spouses. Researchers have found that there is a correlation between the feeling of high confidence and the incidence of infidelity. People holding positions of power have high levels of confidence.

A new study by UCLA researchers found that meditation appeared to help reduce the potential loss of the brain’s gray matter as people age.
The new UCLA Study was published in the recent issue of the online Swiss Journal titled “Frontiers in Psychology” in the “Cognition” section and part of the Research TopicNeuroimaging and Neuropsychology of Meditation states.

Areas of the brain affected by aging (in red) are fewer and less widespread in people who meditate, bottom row, than in people who don’t meditate.

A study published by Cell Press May 9th (volume 153, issue4) in the journal Cell reveals that a blood hormone known as growth differentiation factor 11 (GDF11) declines with age, and old mice injected with this hormone experience a reversal in signs of cardiac aging.To view the press release from this ground breaking study please click on the following link: http://www.eurekalert.org/pub_releases/2013-05/cp-rhf050313.php.

Disclaimer: There could be unintentional errors or omissions in the above post. Always read the actual study abstract and purchase the study at the links included in this post. This post is not meant to be medical advice. I am not a licensed Medical Doctor. If you have an interest in this topic, then always discuss such medical issues, concerns and interests with your own licensed Medical Doctor or other licensed Medical Professional. No person, company or institution mentioned above are affiliated with this blog. No person, company or institution mentioned above has endorsed this blog or this post.

On April 07 2013 a new and extremely important study was published by the peer-reviewed journal Nature Medicine.

This new study clearly demonstrated that the metabolism by Intestinal Microbiota of Dietary L-Carnitine, a Trimethylamine abundant in red meat, produced Trimethylamine-N-Oxide (TMAO) and accelerated the development of Atherosclerosis in mice. This acceleration of Atherosclerosis did not occur, when the test group of mice were concurrently given antibiotics to suppress the population of Intestinal Microbiota.

Copyright

If a specific photo is not our own, we will include a Photo Credit just below the photograph in the Caption area. Any such photos are either in the Public Domain, carry a Creative Commons license for Free use or are used with permission granted by said Copyright Holder.

Videos are linked to only when the originating Video site permits us to do so. The vast majority of linked to videos found on this site are courtesy of YouTube and assorted YouTube Channels.

Affiliations & Disclaimer

Uniquely Toronto and this blogsite are not affiliated with the City of Toronto, in any way.

The City of Toronto does "not" sponsor or endorse the Uniquely Toronto blog, or the Photos and Blog Posts found here.

****************
DISCLAIMER:
****************
All the articles on this site are for entertainment, educational and commentary purposes only, and as such are protected by Laws governing Free Speech. They are not intended to provide, nor replace, medical, health, legal, financial or other professional advice. Each person visiting our site must do their own Due Diligence and always speak with their own Licensed Medical and or Licensed Financial Professional.

In 2017 I have started to post about Medical Cannabis. FDA Disclaimer: The statements on this site have not been evaluated by the US FDA and are not intended to diagnose, treat, cure or prevent any disease.

Your Licensed Medical Doctor must be consulted before
starting any form of treatment.

The information which is posted on the Uniquely Toronto blog should NEVER be considered as being professional medical advice. Vincent Banial is not a Licensed Medical Doctor. As was mentioned earlier in this Disclaimer, all the articles on this site are for entertainment, educational and commentary purposes only.

Anything posted on this Blog is subject to change without notice. I report on events over which I have no control. Stuff happens and things are always subject to change without notice (like life itself).

No endorsement of products and services found in our photos or mentioned in our blog posts is either expressed or implied.

Blog posts may contain unintentional errors and or omissions. Please inform me of any errors that you may find on the blog. Our email address is at the top of the blog.

All posts are for entertainment, educational and commentary purposes only, and as such are protected by Laws governing Free Speech.

Trademarks

Product names, brands, logos and any other trademarks found in our Photos or referred to within our Blog posts, are the property of their respective trademark holders. Any Trademarks found and are not used here for commercial purposes. The trademark owners are not affiliated with Vincent Banial, or the Uniquely Toronto blog, or the Uniquely Tech blog, or the Unique F-Stop blog, or the CLiK CLiK Vic photo site. The trademark owners do "not" sponsor or endorse our Photos or Blog Posts

Published under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 license

The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

Attribution — You must give appropriate credit to Vincent Banial, provide a link back to https://uniquelytoronto.wordpress.com, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

NonCommercial — You may not use the material for commercial purposes.

NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.

No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.